Enact HoldingsNASDAQ: ACT

Enact Holdings (ACT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Nicholas Smith, Japan strategist at CLSA, says Seven & i's restructuring plans may be a case of "too little too late."

7-Eleven's Japanese owner Seven & i has formally rejected a takeover bid tabled by Canadian convenience store giant Alimentation Couche-Tard Inc (TSX:ATD.B) (ACT). ACT, which owns the Circle K chain, announced the surprise $38 billion bid in August, in what would have been the largest takeover of a Japanese corporate in history.

TAMPA, Fla. and STAMFORD, Conn.

RALEIGH, N.C., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact), a leading provider of private mortgage insurance through its insurance subsidiaries, today addressed the updated Private Mortgage Insurer Eligibility Requirements (PMIERs) released by Fannie Mae and Freddie Mac (the GSEs), and the Federal Housing Finance Administration (FHFA) on August 21, 2024 which will be phased-in between March 31, 2025 and September 30, 2026.

Toronto, Ontario--(Newsfile Corp. - Le 19 août/August 2024) - Aduro Clean Technologies Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every three and one quarter (3.25) pre-consolidated common shares. As a result, the outstanding shares of the company will be reduced to approximately 27,174,297 common shares.

-       Newly issued U.S. patent augments Actinium's existing composition of matter patent coverage over Iomab-B and Iomab-ACT targeted radiotherapy conditioning programs -       Pertains to the use of Iomab-ACT with genetically engineered hematopoietic stem cells for treating non-malignant diseases including sickle cell disease, severe combined immunodeficiency disease, β-thalassemia and Fanconi's anemia NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the issuance of U.S. Patent No. 11,912,780 titled, "Anti-CD45-Based Conditioning Methods and Uses Thereof in Conjunction with Gene-Edited Cell Based Therapies" by the United States Patent and Trademark Office (USPTO).

Enact Holdings, Inc. (ACT) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.10 per share a year ago.

- Sickle cell disease affects approximately 100,000 patients in the U.S. annually and is a debilitating and life-threatening condition with high unmet need - Current conditioning with non-targeted chemotherapies provides limited access to potentially curative bone marrow transplant and recently approved gene therapies for sickle cell disease patients - Initial trial focused on conditioning for bone marrow transplant intended to inform subsequent gene therapy conditioning study and provide broader access to cellular therapy for sickle cell patients NEW YORK , July 25, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the FDA clearance of an Investigational New Drug (IND) application to study Iomab-ACT for targeted conditioning prior to a bone marrow transplant (BMT), in patients with sickle cell disease. The study will be conducted in collaboration with the Columbia University and led by Markus Mapara, M.D.